Novartis Wins Herpes Drug Patent Fight Against Teva

By Erin Fuchs

Law360, New York (November 19, 2009, 6:23 PM ET) -- A jury has sided with Novartis AG in a suit it filed claiming Teva Pharmaceuticals USA Inc. infringed the patent for its genital herpes drug Famvir by seeking regulatory approval to market its own generic version.

The jury in the U.S. District Court for the District of New Jersey found in favor of Novartis and against Teva on Wednesday.

According to Cravath Swaine & Moore LLP, which represented Novartis in this matter along with Fitzpatrick, Cella, Harper & Scinto, Teva had already conceded infringement but claimed...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles